Mads Hald Andersen

List of Publications by Year
in descending order

132 papers	5,078 citations	101543 36 h-index	106344 65 g-index
134 all docs	134 docs citations	134 times ranked	7379 citing authors

#	Article	IF	Citations
1	Cytotoxic T Cells. Journal of Investigative Dermatology, 2006, 126, 32-41.	0.7	316
2	The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Scientific Reports, 2015, 5, 16148.	3.3	269
3	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	1.8	265
4	Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research, 2016, 22, 3734-3745.	7.0	234
5	Immune-suppressive properties of the tumor microenvironment. Cancer Immunology, Immunotherapy, 2013, 62, 1137-1148.	4.2	179
6	The Universal Character of the Tumor-Associated Antigen Survivin. Clinical Cancer Research, 2007, 13, 5991-5994.	7.0	155
7	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 2012, 10, 169.	4.4	134
8	Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase. Clinical Cancer Research, 2014, 20, 221-232.	7.0	118
9	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunology, Immunotherapy, 2012, 61, 1791-1804.	4.2	103
10	Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood, 2011, 117, 2200-2210.	1.4	101
11	Regulators of apoptosis: suitable targets for immune therapy of cancer. Nature Reviews Drug Discovery, 2005, 4, 399-409.	46.4	97
12	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Research, 2015, 75, 3747-3759.	0.9	93
13	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine, 2021, 27, 2212-2223.	30.7	88
14	Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2008, 31, 771-780.	2.4	87
15	BRAF inhibition improves tumor recognition by the immune system. OncoImmunology, 2012, 1, 1476-1483.	4.6	82
16	HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients. Cancer Research, 2013, 73, 1764-1776.	0.9	78
17	Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells. Scientific Reports, 2017, 7, 14516.	3.3	77
18	The role of dendritic cells in cancer. Seminars in Immunopathology, 2017, 39, 307-316.	6.1	76

#	Article	IF	Citations
19	Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Seminars in Cancer Biology, 2003, 13, 449-459.	9.6	73
20	Immunogenicity of Constitutively Active V599EBRaf. Cancer Research, 2004, 64, 5456-5460.	0.9	71
21	Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 2091-2103.	4.2	69
22	Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy, 2010, 12, 721-734.	0.7	66
23	Identification of heme oxygenase-1â€“specific regulatory CD8+ T cells in cancer patients. Journal of Clinical Investigation, 2009, 119, 2245-2256.	8.2	64
24	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. PLoS ONE, 2009, 4, e6910.	2.5	64
25	Immunogenicity of Bcl-2 in patients with cancer. Blood, 2005, 105, 728-734.	1.4	60
26	CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. OncoImmunology, 2016, 5, e1238541.	4.6	56
27	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4⁺T cells. OncoImmunology, 2013, 2, e23991.	4.6	52
28	Cancer treatment: the combination of vaccination with other therapies. Cancer Immunology, Immunotherapy, 2008, 57, 1735-1743.	4.2	48
29	Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2. Cancer Research, 2011, 71, 2038-2044.	0.9	45
30	Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy, 2016, 18, 1043-1055.	0.7	45
31	Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase. PLoS ONE, 2012, 7, e34568.	2.5	43
32	The Balance Players of the Adaptive Immune System. Cancer Research, 2018, 78, 1379-1382.	0.9	43
33	The Immunogenicity of the hTERT540-548 Peptide in Cancer. Clinical Cancer Research, 2008, 14, 4-7.	7.0	42
34	Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy, 2011, 13, 822-834.	0.7	39
35	Analysis of VÎ´1 T cells in clinical grade melanoma-infiltrating lymphocytes. OncoImmunology, 2012, 1, 1297-1304.	4.6	39
36	Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv154-djv154.	6.3	39

#	Article	IF	Citations
37	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
38	MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells. Cancer Immunology Research, 2019, 7, 1472-1484.	3.4	39
39	Spontaneous Immunity against Bcl-xL in Cancer Patients. Journal of Immunology, 2005, 175, 2709-2714.	0.8	38
40	Durable Clinical Responses and Long-Term Follow-Up of Stage IIIâ€“IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Studyâ€”A Brief Research Report. Frontiers in Immunology, 2018, 9, 2145.	4.8	37
41	Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-Î³ Enhances Anticancer Responses of Cell Products for Infusion. Journal of Investigative Dermatology, 2013, 133, 545-552.	0.7	36
42	The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer. Current Cancer Drug Targets, 2014, 14, 337-347.	1.6	36
43	Anti-regulatory T cells. Seminars in Immunopathology, 2017, 39, 317-326.	6.1	35
44	Peptide vaccination directed against IDO1-expressing immune cells elicits CD8⁺ and CD4⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. , 2020, 8, e000605.		34
45	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. OncoImmunology, 2016, 5, e1202391.	4.6	33
46	The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. OncoImmunology, 2018, 7, e1390641.	4.6	33
47	The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase. Cancer Immunology, Immunotherapy, 2012, 61, 1289-1297.	4.2	32
48	Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4⁺ T cells in cutaneous T-cell lymphoma. OncoImmunology, 2019, 8, e1641387.	4.6	32
49	Arginase 1â€“Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Antiâ€“PD-1 Checkpoint Blockade. Cancer Immunology Research, 2021, 9, 1316-1326.	3.4	32
50	The Targeting of Indoleamine 2,3 Dioxygenase â€Mediated Immune Escape in Cancer. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 19-24.	2.5	30
51	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology, 2018, 7, e1433521.	4.6	30
52	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology, 2016, 5, e1207842.	4.6	29
53	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 637420.	2.8	29
54	MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. Cancers, 2020, 12, 1229.	3.7	28

#	Article	IF	Citations
55	Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine, 2013, 31, 639-646.	3.8	27
56	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134.	6.4	27
57	Frequent adaptive immune responses against arginase-1. OncoImmunology, 2018, 7, e1404215.	4.6	27
58	High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer Journal, 2019, 9, 8.	6.2	27
59	Therapeutic Cancer Vaccines in Combination with Conventional Therapy. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	26
60	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. OncoImmunology, 2013, 2, e23288.	4.6	25
61	Bioinformatics for cancer immunotherapy target discovery. Cancer Immunology, Immunotherapy, 2014, 63, 1235-1249.	4.2	25
62	Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. OncoImmunology, 2015, 4, e968480.	4.6	25
63	Establishing the pig as a large animal model for vaccine development against human cancer. Frontiers in Genetics, 2015, 6, 286.	2.3	24
64	<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 ⁺ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. OncoImmunology, 2020, 9, 1751561.	4.6	24
65	Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in SÃ©zary syndrome. Blood Cancer Journal, 2020, 10, 57.	6.2	24
66	Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cellular Immunology, 2012, 273, 1-9.	3.0	23
67	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. Stem Cell Investigation, 2017, 4, 77-77.	3.0	22
68	RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunology, Immunotherapy, 2008, 57, 1871-1878.	4.2	21
69	Indoleamine 2,3-dioxygenase vaccination. OncoImmunology, 2015, 4, e983770.	4.6	20
70	PD-L1-specific T cells. Cancer Immunology, Immunotherapy, 2016, 65, 797-804.	4.2	20
71	Low antigen dose formulated in CAF09 adjuvant Favours a cytotoxic T-cell response following intraperitoneal immunization in GÃ¶ttingen minipigs. Vaccine, 2017, 35, 5629-5636.	3.8	19
72	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Frontiers in Immunology, 2018, 9, 2264.	4.8	19

#	Article	IF	Citations
73	The T-winÂ® technology: immune-modulating vaccines. Seminars in Immunopathology, 2019, 41, 87-95.	6.1	19
74	Anti-cancer immunotherapy: breakthroughs and future strategies. Seminars in Immunopathology, 2019, 41, 1-3.	6.1	19
75	Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21. Cytotherapy, 2016, 18, 1187-1196.	0.7	18
76	The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. OncoImmunology, 2020, 9, 1771142.	4.6	18
77	Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. Frontiers in Immunology, 2020, 11, 595035.	4.8	17
78	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	3.7	17
79	Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investigation, 2016, 3, 95-95.	3.0	16
80	Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer Immunology, Immunotherapy, 2019, 68, 1901-1907.	4.2	16
81	CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53. Clinical Cancer Research, 2009, 15, 1543-1549.	7.0	15
82	The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunology, Immunotherapy, 2009, 58, 665-675.	4.2	15
83	Sorted peripheral blood cells identify <i>CALR</i> mutations in B- and T-lymphocytes. Leukemia and Lymphoma, 2018, 59, 973-977.	1.3	15
84	Interleukin-26 (IL-26) is a novel anti-microbial peptide produced by T cells in response to staphylococcal enterotoxin. Oncotarget, 2018, 9, 19481-19489.	1.8	15
85	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology, 2018, 7, e1468957.	4.6	15
86	Cancer immune therapy for lymphoid malignancies: recent advances. Seminars in Immunopathology, 2019, 41, 111-124.	6.1	15
87	The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G. Cellular Immunology, 2018, 324, 14-23.	3.0	14
88	Immunoprofiles of colorectal cancer from Lynch syndrome. OncoImmunology, 2019, 8, e1515612.	4.6	14
89	Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application. Journal of Skin Cancer, 2011, 2011, 1-6.	1.2	13
90	Peripheral memory T cells specific for Arginase-1. Cellular and Molecular Immunology, 2019, 16, 718-719.	10.5	13

#	Article	IF	Citations
91	The targeting of tumor-associated macrophages by vaccination. Cell Stress, 2019, 3, 139-140.	3.2	13
92	Inflammation induced PD-L1-specific T cells. Cell Stress, 2019, 3, 319-327.	3.2	13
93	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunology, Immunotherapy, 2020, 69, 315-324.	4.2	12
94	Self-reactive T cells: suppressing the suppressors. Cancer Immunology, Immunotherapy, 2014, 63, 313-319.	4.2	11
95	Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 578349.	4.8	11
96	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. PLoS ONE, 2015, 10, e0131934.	2.5	11
97	IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status. Cancer Immunology Research, 2022, 10, 571-580.	3.4	11
98	CD4 responses against IDO. OncoImmunology, 2012, 1, 1211-1212.	4.6	10
99	The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy. OncoImmunology, 2017, 6, e1358334.	4.6	10
100	Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFÎ²-expressing cancer cells in a TGFÎ²-dependent manner. Cellular and Molecular Immunology, 2021, 18, 415-426.	10.5	10
101	Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecologic Oncology, 2021, 162, 686-693.	1.4	10
102	Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNÎ³, Following Recognition of Autologous Tumor-Antigens. Frontiers in Immunology, 2021, 12, 705422.	4.8	10
103	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
104	Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens. Cancers, 2020, 12, 3045.	3.7	9
105	Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. OncoImmunology, 2022, 11, 2026020.	4.6	9
106	Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunology, Immunotherapy, 2007, 56, 527-533.	4.2	8
107	Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses. OncoImmunology, 2012, 1, 441-447.	4.6	7
108	Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study. Cancers, 2021, 13, 911.	3.7	7

#	Article	IF	Citations
109	FOXP3-specific immunity. OncoImmunology, 2013, 2, e26247.	4.6	6
110	Cancer and autoimmunity. Seminars in Immunopathology, 2017, 39, 241-243.	6.1	6
111	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	2.2	6
112	Immunoregulatory antigensâ€"novel targets for cancer immunotherapy. Chinese Clinical Oncology, 2018, 7, 19-19.	1.2	6
113	An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. OncoImmunology, 2021, 10, .	4.6	5
114	Characterization of TGFÎ²-specific CD4+T cells through the modulation of TGFÎ² expression in malignant myeloid cells. Cellular and Molecular Immunology, 2021, 18, 2575-2577.	10.5	5
115	(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. PLoS ONE, 2016, 11, e0168210.	2.5	5
116	Characterization of T-cell responses against IÎºBÎ± in cancer patients. OncoImmunology, 2012, 1, 1290-1296.	4.6	4
117	Spontaneous presence of FOXO3-specific T cells in cancer patients. OncoImmunology, 2014, 3, e953411.	4.6	4
118	The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2016, 136, 866-869.	0.7	4
119	Keeping each other in check: A reciprocal relationship between cytokines and miRNA. Cell Cycle, 2013, 12, 2171-2171.	2.6	3
120	Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology. Immunologic Research, 2014, 60, 156-164.	2.9	3
121	Novel understanding of self-reactive T cells. OncoImmunology, 2016, 5, e1083672.	4.6	3
122	Expression and function of Kv1.3 channel in malignant T cells in SÃ©zary syndrome. Oncotarget, 2019, 10, 4894-4906.	1.8	3
123	Possible benefits of the targeting of indoleamine 2,3-dioxygenase (IDO) in hepatitis B vaccination. Vaccine, 2011, 29, 3728.	3.8	2
124	Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells, 2012, 1, 51-60.	4.1	2
125	Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy. Leukemia and Lymphoma, 2019, 60, 3296-3299.	1.3	2
126	Neo-antigen specific memory T-cell responses in healthy individuals. OncoImmunology, 2019, 8, e1599640.	4.6	2

#	Article	IF	Citations
127	Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab. Cancer Research, 2022, 82, CT535-CT535.	0.9	1
128	T-cell dependent immunoselection. OncoImmunology, 2012, 1, 1003-1003.	4.6	0
129	Tumor-Produced Immune Regulating Factors. , 2013, , 287-306.		0
130	Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies. , 2013, , 347-359.		0
131	PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients.. Journal of Clinical Oncology, 2014, 32, 11083-11083.	1.6	0
132	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology, 2022, 13, .	4.8	0